FDA clears Accelerate Diagnostics’ bloodstream infection test

The PhenoTest BC kit can identify bloodstream infection-causing bacteria or yeast and provide antibiotic sensitivity information more quickly than existing tests. Image: Accelerate Diagnostics

Accelerate Diagnostics earned 510(k) clearance for a test that identifies the organism behind bloodstream infections and provides information about its antibiotic sensitivity.

The PhenoTest BC Kit, which runs on the company’s Pheno System, is the first test to identify the bacteria or yeast behind a blood infection and supply information about which antibiotics it is likely to respond to, the FDA said in a statement.

It identifies 14 species of bacteria and two species of yeast and provides antibiotic sensitivity information on 18 antibiotics, the FDA said. The test works by comparing the DNA of the infection-causing bacteria or yeast to DNA that is unique to specific organisms. The organism is then mixed with different antibiotics to determine which ones curb the organism’s growth.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Identification takes about an hour and a half, while antibiotic sensitivity information may be generated in as few as six and a half hours, according to the statement. Existing antibiotic susceptibility tests may take 24 to 48 hours to return results, the FDA said.

"By identifying organisms and knowing earlier which antibiotics the organism is likely to respond to, health care professionals can treat patients with bloodstream infections more appropriately," said Alberto Gutierrez, director of the Office of In Vitro Diagnostics and Radiological Health at the FDA's Center for Devices and Radiological Health.

Bloodstream infections are particularly dangerous in infants, the elderly and those with compromised immune function. Rapid identification of appropriate antibiotics can lead to early intervention to head off complications, such as septic shock.

Suggested Articles

Inotrem and Roche’s diagnostics division have upgraded their years-long collaboration on a plasma test for septic shock, with a new worldwide deal.

As GlaxoSmithKline looks to start a 23andMe-partnered test this year, the Big Pharma is increasingly looking to tech for its R&D.

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.